Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study
Adjuvant docetaxel-based chemotherapy is frequently used in the treatment of operable early breast cancer (EBC). This study investigated patterns of docetaxel use in patients with EBC in real-world clinical practice in China.
This was a multicenter, prospective, observational study of Chinese women with operable breast cancer in tier 1 non-oncology-specific hospitals and other city hospitals in China. Adult Chinese female patients (≥ 18 years) with newly diagnosed breast cancer who underwent surgery and received docetaxel-containing adjuvant chemotherapy were eligible for inclusion. The primary end point of the study was to assess patterns of docetaxel use for adjuvant therapy in Chinese clinical practice. Secondary end points included factors associated with treatment selection, patterns of G-CSF use and safety.
In total, 502 patients were enrolled, 475 of whom were included in the analysis. The results showed that 31.6% of patients received docetaxel and anthracyclines in combination, 47.2% received docetaxel and anthracyclines sequentially, 18.5% received docetaxel and other medication either in combination or sequentially and 2.7% received ‘other’ chemotherapy regimens. Factors influencing selection of docetaxel/anthracycline in combination versus sequentially included age, breast cancer subgroup, PR status, and preoperative neoadjuvant chemotherapy. A total of 258 (54.3%), 35 (7.4%), and 108 (22.7%) patients received G-CSF as primary prevention, secondary prevention and treatment, respectively. Treatment-emergent adverse events (TEAEs) occurred in 54.5% (259) of patients, and the most frequently reported TEAEs (≥ 5% of patients) included bone marrow failure (10.1%), granulocytopenia (9.9%), nausea (8.8%) and vomiting (6.9%). Neutropenia and febrile neutropenia were reported by 10 and 12 patients, respectively.
Docetaxel for adjuvant chemotherapy of operable EBC in China was most commonly given in combination or sequentially with anthracyclines. The study also showed that in China G-CSF is most frequently used as primary prophylactic, and no unexpected safety events were observed during docetaxel treatment.
KeywordsBreast cancer Docetaxel G-CSF Oncology Real world Treatment patterns
We thank all study participants and their families as well as all of the investigators.
This study was sponsored by Sanofi (China). The publication fees for this manuscript were funded by Sanofi. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Editorial assistance for this manuscript was funded by Sanofi and provided by Tigermed and Rude Health Consulting.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.
Hui Xie, Jinping Liu, Shiyou Yu, Yiding Chen, Min Zheng, Yongchuan Deng, Shu Wang, Jun Jiang, Yafen Li, Huiping Li, Hua Kang, Chunhui Zhang, Guo-Jun Zhang, Fengxi Su, Aiqun Cheng and Shui Wang have nothing to disclose.
Compliance with Ethics Guidelines
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan and data set specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of our trial participants. Further details on Sanofi’s data sharing criteria, eligible studies and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/.
- 6.Henry NL, Somerfield MR, Krop IE. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American society of clinical oncology endorsement of cancer care ontario guideline recommendations summary. J Oncol Pract. 2016;12(5):482–4. https://doi.org/10.1200/jop.2016.011205.CrossRefGoogle Scholar
- 7.Denduluri N, Somerfield MR, Eisen A, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American society of clinical oncology guideline adaptation of the cancer care ontario clinical practice guideline. J Clin Oncol. 2016;34(20):2416–27. https://doi.org/10.1200/jco.2016.67.0182.CrossRefPubMedGoogle Scholar
- 8.Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (London, England). 2012;379(9814):432–44. https://doi.org/10.1016/s0140-6736(11)61625-5.CrossRefGoogle Scholar
- 9.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (London, England). 2005;365(9472):1687–717. https://doi.org/10.1016/s0140-6736(05)66544-0.
- 15.Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007;(4):Cd004421. https://doi.org/10.1002/14651858.cd004421.pub2.
- 17.Watanabe T, Kuranami M, Inoue K, et al. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer. 2017;123(5):759–68. https://doi.org/10.1002/cncr.30421.CrossRefPubMedGoogle Scholar
- 18.Mitchell S, Li X, Woods M, et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract. 2016;22(5):702–16. https://doi.org/10.1177/1078155215625459.CrossRefPubMedGoogle Scholar
- 19.Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178–84. https://doi.org/10.1200/jco.2005.09.102.CrossRefPubMedGoogle Scholar
- 21.Zhu X, Bouganim N, Vandermeer L, Dent SF, Dranitsaris G, Clemons MJ. Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience. Curr Oncol (Toronto, Ont). 2012;19(4):e239–43. https://doi.org/10.3747/co.19.948.CrossRefPubMedCentralGoogle Scholar
- 23.Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–9. https://doi.org/10.1200/jco.2003.09.081.CrossRefPubMedGoogle Scholar
- 24.Yerushalmi R, Goldvaser H, Sulkes A, et al. Adjuvant docetaxel and cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 & 12 in breast cancer patients: a retrospective analysis. PLoS One. 2014;9(10):e107273. https://doi.org/10.1371/journal.pone.0107273.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27(21):3540–6. https://doi.org/10.1200/jco.2008.20.8793.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Hendler D, Rizel S, Yerushalmi R, et al. Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study. Am J Clin Oncol. 2011;34(6):619–24. https://doi.org/10.1097/coc.0b013e3181f94716.CrossRefPubMedGoogle Scholar
- 32.Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us Oncology Research Trial 9735. J Clin Oncol. 2009;27(8):1177–83. https://doi.org/10.1200/jco.2008.18.4028.CrossRefPubMedGoogle Scholar
- 34.Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21(6):968–75. https://doi.org/10.1200/jco.2003.04.040.CrossRefPubMedGoogle Scholar
- 35.Sparano JA, O’Neill A, Schaefer PL, Falkson CI, Wood WC. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol. 2000;18(12):2369–77. https://doi.org/10.1200/jco.2000.18.12.2369.CrossRefPubMedGoogle Scholar
- 38.Mackey JR, Pienkowski T, Crown J, et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann Oncol. 2016;27(6):1041–7. https://doi.org/10.1093/annonc/mdw098.CrossRefPubMedGoogle Scholar
- 39.Kim SB, Sayeed A, Villalon AH, et al. Safety analysis of adjuvant chemotherapy with docetaxel administered with or without anthracyclines to early stage breast cancer patients: combined results from the Asia-Pacific breast initiatives I and II. Asian Pac J Cancer Prev. 2016;17(2):697–702.CrossRefGoogle Scholar
- 40.Kim SB, Kok YT, Thuan TV, Chao TY, Shen ZZ. safety results of Docetaxel-(Taxotere(R))-based chemotherapy in early breast cancer patients of Asia-Pacific region: Asia-Pacific Breast Initiative II. J Breast Cancer. 2015;18(4):356–64. https://doi.org/10.4048/jbc.2015.18.4.356.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Eiermann W, Pienkowski T, Crown J, et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011;29(29):3877–84. https://doi.org/10.1200/jco.2010.28.5437.CrossRefPubMedGoogle Scholar
- 43.DaCosta Byfield S, Buck PO, Blauer-Peterson C, et al. ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the united states: a real-world retrospective study. J Oncol Pract. 2016;12(2):159–67. https://doi.org/10.1200/jop.2015.004747.CrossRefGoogle Scholar
- 49.Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 2006;17(8):1205–12. https://doi.org/10.1093/annonc/mdl135.CrossRefPubMedGoogle Scholar
- 50.Maenpaa J, Varthalitis I, Erdkamp F, et al. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer–further observations from the IMPACT solid study. Breast (Edinburgh, Scotland). 2016;25:27–33. https://doi.org/10.1016/j.breast.2015.11.007.CrossRefGoogle Scholar